En DE FR ES PL
Slimiya - instructions for use, reviews, analogs and form of release (capsules or tablets 10 mg and 15 mg) drugs for the treatment of obesity or weight loss and weight loss in adults, children and pregnancy. Composition and alcohol

Slimiya - instructions for use, reviews, analogs and form of release (capsules or tablets 10 mg and 15 mg) drugs for the treatment of obesity or weight loss and weight loss in adults, children and pregnancy. Composition and alcohol

In this article, you can read the instructions for using the drugSlimia. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Slimia in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Slimia in the presence of existing structural analogues. Use to treat obesity or weight loss and weight loss in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

 

Slimia - a tool for the treatment of obesity central action. The mechanism of action is due to selective inhibition of reuptake of serotonin and norepinephrine, to a lesser extent - dopamine. Accelerates the attack and prolongs the sense of saturation, which leads to a reduction in food intake. Increases energy consumption by stimulating thermogenesis through the mediated activation of beta3-adrenergic receptors. It acts on both sides of the energy balance and helps to reduce body weight. Sibutramine (the active substance of the preparation Slimia) and its metabolites do not release monoamines and are not monoamine oxidase (MAO) inhibitors, do not have an affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, benzodiazepine and N-methyl-D-aspartate (NMDA) receptors.

 

Composition

 

Sibutramine + excipients.

 

Pharmacokinetics

 

After oral administration sibutramine is rapidly absorbed from the gastrointestinal tract (GIT). Almost completely metabolized in the liver with the participation of isoenzymes of the cytochrome CYP3A4 system with the formation of mono- (dismethylsibutramine) and di-dimethyl (di-dimethylsibutramine) forms of active metabolites (M1 and M2), and also by hydroxylation and conjugation with formation of inactive metabolites.Quickly and well distributed in tissues. Binding to plasma proteins: sibutramine - 97%, M1 and M2 - 94%. It is excreted mostly by kidneys in the form of inactive metabolites.

 

Indications

  • obesity;
  • alimentary obesity - as part of maintenance complex therapy in patients with excessive body weight and body mass index of 30 kg / m2 and more;
  • overweight (excess body weight) in patients with a body mass index of 27 kg / m 2 and more in the presence of risk factors, namely type 2 diabetes (insulin-independent) or hyperlipidemia.

 

Forms of release

 

Capsules 10 mg and 15 mg (sometimes mistakenly called tablets).

 

Instructions for use and dosing regimen

 

The initial dose is 10 mg per day. With insufficient effectiveness when used in this dose (a decrease in body weight of less than 2 kg in 4 weeks) and with good tolerability, the dose can be increased to 15 mg per day. In the absence of effect when administered at a dose of 15 mg per day (weight loss of less than 2 kg for 4 weeks) sibutramine should be discontinued.

 

In patients who do not adequately respond to therapy, that is, within 3 months they can not reach 5% of the level of weight loss from the baseline, the duration of application should not exceed 3 months.

 

The course of treatment is no more than 1 year, since there is no data on the efficacy and safety of longer-term use.

 

Do not continue to use the drug Slymia, if after the achieved weight loss during further therapy, the patient again adds a mass of 3 kg or more.

 

Side effect

  • loss of appetite;
  • constipation;
  • dry mouth;
  • nausea;
  • transient increase in hepatic enzyme activity;
  • insomnia;
  • headaches, dizziness;
  • anxiety;
  • paresthesia (spontaneous sensations of burning, tingling, crawling);
  • increased sweating;
  • change in taste;
  • convulsive seizures;
  • tachycardia, palpitations;
  • increased blood pressure (BP);
  • redness of the skin with a feeling of warmth;
  • exacerbation of hemorrhoids;
  • acute interstitial nephritis;
  • mesangiocapillary glomerulonephritis;
  • thrombocytopenia;
  • purple Shenlaine-Genocha.

 

Most often, side effects occur at the beginning of therapy (in the first 4 weeks), their severity and frequency of occurrence diminish over time.

 

Contraindications

  • organic cause of obesity;
  • known and established severe eating disorders (anorexia nervosa or bulimia nervosa);
  • mental illness;
  • Tourette's syndrome;
  • ischemic heart disease (IHD);
  • chronic heart failure in the stage of decompensation;
  • congenital heart defects;
  • occlusive diseases of peripheral arteries;
  • tachycardia, arrhythmia;
  • disorders of cerebral circulation (including transient);
  • uncontrolled arterial hypertension (blood pressure more than 145/90 mm Hg);
  • hyperthyroidism (a complex of symptoms caused by increased production and inadequately high secretion of thyroid hormones into the blood);
  • severe renal dysfunction;
  • severe violations of liver function;
  • benign prostatic hyperplasia with the formation of residual urine;
  • pheochromocytoma (tumor of adrenal medulla);
  • glaucoma (a constant or periodic increase in intraocular pressure above a tolerated level for a given person);
  • established pharmacological narcotic and alcohol dependence;
  • pregnancy, lactation (breastfeeding);
  • simultaneous administration or period up to 2 weeks after withdrawal of MAO inhibitors or other drugs that have an inhibitory effect on the central nervous system (CNS), namely antidepressants, antipsychotics, tryptophan, or other medications to reduce body weight;
  • hypersensitivity to sibutramine.

 

Application in pregnancy and lactation

 

The drug Slymia is contraindicated for use in pregnancy and lactation (breastfeeding).

 

Women of childbearing age in the period of treatment should apply adequate methods of contraception.

 

Use in children

 

Do not use in children and adolescents under the age of 18 due to lack of sufficient clinical experience in this category of patients.

 

Application in elderly patients

 

Do not use in people older than 65 years due to the lack of sufficient clinical experience using the drug Slymia in geriatric patients.

 

special instructions

 

Apply only in those cases when all measures to reduce body weight are ineffective (that is, a decrease in body weight is less than 5 kg within 3 months).

 

Treatment should be conducted only within the framework of complex therapy for weight loss under the supervision of a doctor who has practical experience in the treatment of obesity. Complex therapy includes both changing diet and lifestyle, and increasing physical activity. Thus, the prerequisites for a permanent change in eating habits and lifestyle are formed, which are necessary to maintain the achieved weight loss after the abolition of drug therapy.

 

With caution apply simultaneously with drugs that increase the QT interval on the electrocardiogram (ECG), in patients with hypokalemia and hypomagnesemia, epilepsy, with violations of liver function of mild and moderate severity (as there may be an asymptomatic increase in the concentration of sibutramine in the blood plasma), with impaired renal function of mild and moderate severity (since inactive metabolites are partially excreted by the kidneys), in patients with motor tics or vocalisms in a family history, concomitantly with drugs, n Witzlaus blood pressure and heart rate (HR), including drugs used for coughs, allergies and colds.

 

During the treatment period it is necessary to control blood pressure and heart rate: in the first 2 months of therapy - every 2 weeks, then monthly. In patients with arterial hypertension (blood pressure more than 145/90 mm Hg), these parameters should be monitored carefully and, if necessary, more often. If the blood pressure during repeated measurement twice exceeded 145/90 mm of mercury, then sibutramine should be discarded.

 

Regular medical supervision during treatment should pay attention to progressive dyspnea, chest pain and swelling, although the relationship between sibutramine intake and the development of primary pulmonary hypertension is not established.

 

Reactions to the abolition of Slymia (headache, increased appetite) are rare.

 

During the treatment period, you should not drink alcohol because of the need to follow a diet.

 

Influence on the ability to drive vehicles and control mechanisms

 

At present, the influence of sibutramine on the ability to engage in potentially hazardous activities has not been established. However, it is impossible to exclude the possibility of such an impact. Caution should be used in the preparation of Slimia in patients whose activities require increased attention and speed of psychomotor reactions.

 

Drug Interactions

 

When used simultaneously with agents that inhibit the activity of the isoenzyme CYP3A4 (ketoconazole, erythromycin, troleandomycin, cyclosporin), plasma concentrations of sibutramine metabolites increase, and the QT interval slightly increases.

 

With simultaneous use with rifampicin, phenytoin, carbamazepine, phenobarbital, dexamethasone, antibiotics of the macrolide group, it is possible to accelerate the metabolism of sibutramine.

 

With simultaneous application of Slymia with selective serotonin reuptake inhibitors (citalopram, fluoxetine, paroxetine, sertraline), 5-HT1 receptor agonists, derivatives of ergot alkaloids, opioid analgesics, central antitussive agents, the risk of developing serotonin syndrome increases.

 

Analogues of the drug Slimia

 

Structural analogs for the active substance:

  • Goldline;
  • Lindax;
  • Meridia;
  • Sibutramine.

 

Analogues of the drug Slimia by the pharmacological group (regulators of appetite):

  • Aira rhizome;
  • Goldline;
  • Dietplast;
  • Dietress;
  • Dietrin;
  • Dr. Theiss;
  • Gastric collection number 3;
  • A thousand-thousandth grass;
  • Coriander fruit;
  • Lindax;
  • Meridia;
  • Miniface;
  • Dandelion roots;
  • Wormwood bitter grass;
  • Reduxine;
  • Sibutramine;
  • Super System-Six;
  • Triméks;
  • Citrimax.

 

Response of a therapist

 

I want to tell you about cases of uncontrolled treatment with Slimia, which were in my practice. In order to get rid of excess weight, the patients took this medication without going through the preliminary examination and simply without consulting any of the doctors. As a result, two were hospitalized with hypertensive crises. As it turned out later, both had high arterial pressure for a long time before starting the drug, but they did not deal with this problem. In one patient, after a spontaneous treatment with Slimia, a severe form of glaucoma was diagnosed. The woman knew that she had increased intraocular pressure, but decided not to pay attention to it, and seriously tackled the problem of excess weight. Before buying a drug Slymiya in the pharmacy, do not be lazy to go to the reception to your therapist and consult with him.

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions